BioCardia (NASDAQ:BCDA) Releases Earnings Results, Beats Estimates By $0.05 EPS

BioCardia (NASDAQ:BCDA) announced its quarterly earnings data on Wednesday. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.05, FiscalAI reports.

Here are the key takeaways from BioCardia’s conference call:

• Japan’s PMDA supported advancing CardiAMP toward a Shonin approval submission, which BioCardia expects to file in the fourth quarter of 2026. The company estimates an initial indication of roughly 20,000 patients, with approval potentially about 12 months after submission.
• FDA feedback indicated that the ongoing CardiAMP Heart Failure II trial could serve as the confirmatory study supporting U.S. premarket approval, with no safety or delivery concerns raised. BioCardia is continuing enrollment and discussing how to define the quality-of-life component of the primary endpoint.
• FDA also identified potential approval pathways for the Helix transendocardial delivery catheter, including simultaneous clearance with CardiAMP or a de novo route. Approval could strengthen BioCardia’s partnering opportunities and facilitate future cardiac biologic therapies.
• Heart Failure II enrollment remains slow, with four active recruiting sites and no disclosed total enrollment; management said accelerating enrollment would require additional resources. The company may pursue modest financing to speed the program, creating potential dilution.
• BioCardia ended the quarter with $5.4 million in cash and said its runway extends into 2027, while raising $4.9 million through its at-the-market facility. Operating cash use was $1.7 million in the quarter, and management said available capital should fund the planned Japan submission.

BioCardia Stock Performance

Shares of BCDA stock opened at $0.93 on Friday. The firm’s 50-day moving average is $0.94 and its 200-day moving average is $1.08. The stock has a market cap of $10.57 million, a price-to-earnings ratio of -1.45 and a beta of 0.48. BioCardia has a 52-week low of $0.75 and a 52-week high of $2.29.

Wall Street Analyst Weigh In

A number of research firms have commented on BCDA. HC Wainwright reaffirmed a “buy” rating and set a $25.00 target price on shares of BioCardia in a report on Tuesday, June 9th. Weiss Ratings reissued a “sell (e+)” rating on shares of BioCardia in a research note on Friday, July 17th. Zacks Research raised shares of BioCardia from a “strong sell” rating to a “hold” rating in a research note on Tuesday. Finally, Wall Street Zen upgraded shares of BioCardia to a “sell” rating in a report on Saturday, July 18th. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, BioCardia currently has a consensus rating of “Hold” and a consensus price target of $25.00.

Insiders Place Their Bets

In other BioCardia news, Director Simon H. Stertzer purchased 39,000 shares of the business’s stock in a transaction on Tuesday, June 23rd. The stock was acquired at an average price of $1.00 per share, with a total value of $39,000.00. Following the acquisition, the director directly owned 166,338 shares of the company’s stock, valued at $166,338. This trade represents a 30.63% increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In the last quarter, insiders acquired 142,700 shares of company stock valued at $133,758. 17.40% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Geode Capital Management LLC boosted its holdings in shares of BioCardia by 70.4% during the fourth quarter. Geode Capital Management LLC now owns 66,003 shares of the company’s stock worth $83,000 after acquiring an additional 27,263 shares during the period. DRW Securities LLC bought a new position in shares of BioCardia during the fourth quarter worth approximately $72,000. Finally, Cetera Investment Advisers acquired a new stake in BioCardia during the 2nd quarter worth approximately $40,000. 20.57% of the stock is owned by institutional investors.

About BioCardia

BioCardia, Inc is a clinical-stage biotechnology company dedicated to developing novel cell-based therapies for patients with cardiovascular disease. The company’s core focus lies in advancing regenerative medicine approaches that address both chronic heart failure and acute myocardial infarction. BioCardia leverages proprietary delivery technologies to optimize the targeted administration of therapeutic cells directly into the heart muscle.

The company’s flagship products include the Helix Transendocardial Delivery System and the CardiAMP Cell Therapy System.